Open Access
Subscription or Fee Access
Parkinson’s Disease: A Brief Review
Abstract
Parkinson’s disease (PD) is second most common neurodegenerative disorder after Alzheimer’s. Mainly an imbalance of neurotransmitters in certain regions of the brain are the cause of PD, and the presence of intra- cellular inclusion bodies known as Lewy bodies are also responsible for PD. For the treatment of PD, Dopaminergic and Cholinergic system drugs are used. In the dopaminergic system, dopamine analoge, dopamine agonist, MAO-B inhibitor, COMT inhibitor, Peripheral decarboxylase inhibitor and Dopamine Facilitators are used and in the cholinergic system, Anticholinergic drugs and Antihistaminic drugs are used.
Keywords: L-dopa and carbidopa, Parkinson’s disease, Pharmacologic treatment
Cite this Article: Sukriti Vishwas, Rinku Mathappan, P Maunika. Parkinson’s Disease: A Brief Review. International Journal of Molecular Biotechnology. 2019; 5(1) 11–14p.
Keywords: L-dopa and carbidopa, Parkinson’s disease, Pharmacologic treatment
Cite this Article: Sukriti Vishwas, Rinku Mathappan, P Maunika. Parkinson’s Disease: A Brief Review. International Journal of Molecular Biotechnology. 2019; 5(1) 11–14p.
Full Text:
PDFDOI: https://doi.org/10.37628/ijmb.v5i1.412
Refbacks
- There are currently no refbacks.